Fig. 1 · Structure

Documents & Downloads

Clozapine

Cat. No. A10236 CAS 5786-21-0
Clozapine displays a broad range of pharmacological actions; the antipsychotic effects are thought to be mediated principally by 5-HT2A/2C and dopamine receptor blockade.

In Stock

Publications for Clozapine

6 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Madeleine S A Tan, .et al. , Mol Pharm, 2022, Sep 23 PMID: 36149013
  3. Madeleine S. A. Tan, .et al. , Gels, 2022, Jan; 8(1): 38 PMID: 35049572
  4. Milan D Valyear, .et al. , Nat Commun, 2020, Jul 28;11(1):3764 PMID: 32724058
  5. Yutaro Kobayashi, .et al. , Transl Psychiatry, 2019, 9:181 PMID: 31371697
  6. M.D. Valyear, .et al. , bioRxiv, 2018, 2018

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Clozapine showed limited enhancement of dopamine D2 receptor surface expression in transfected HEK293T cells: its maximum response after 24 h was approximately 30% of the haloperidol response. This receptor-trafficking endpoint does not measure binding affinity or establish functional receptor activation. [1]

Clozapine partially inhibited recombinant ErbB1, ErbB2 and ErbB4 kinase activity in a non-reducing biochemical assay. The lowest concentrations reported as significant were 3 μM for ErbB2 and 30 μM for ErbB1 and ErbB4. These thresholds are assay-dependent and do not establish a clinical mechanism. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
5-HT2

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 206 nM Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay [PMID: 22243698]
CHO IC50 3.6 μM Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits [PMID: 23812503]
CHO IC50 4.1 x 10 Displacement of [3H]methyl-spiperone from human recombinant dopamine D4.4 receptor expressed in CHO cells measured after 60 mins by scintillation counting method [PMID: 27876250]
CHO EC50 56 μM Cytotoxicity against CHO cells by MTT assay [PMID: 17870534]
HEK293 IC50 650 nM Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay [PMID: 23675993]
WI-38 EC50 23.26 μM Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay [PMID: 17893158]
WI-38 CC50 40 μM Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay [PMID: 17893158]

Clozapine Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Clozapine from 3 published references. In vitro models include human A431 epidermoid carcinoma cells without EGF stimulation.

Clozapine In Vitro Studies

Clozapine reduced ligand-stimulated ErbB phosphorylation, with reported cellular IC50 values of approximately 47 μM for ErbB1 in U87MG cells and 16 μM for ErbB4 in rat cortical neurons. Responses depended on model and stimulation: A431 cells showed less inhibition with EGF, and 100 μM clozapine increased basal ErbB1 phosphorylation approximately twofold without EGF. [2]

Limited enhancement of dopamine D2 receptor surface expression

Cell-based study · HEK293T cells transiently expressing extracellular FLAG-tagged human D2 long receptor [1]

Clozapine produced a lower maximum surface-receptor enhancement than haloperidol or olanzapine in a 24 h concentration–response experiment. A separate multi-drug comparison did not find the clozapine group significantly different from vehicle. These are surface-expression endpoints, not binding affinity or functional agonism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maximum clozapine-induced increase in cell-surface D2R relative to haloperidol responserelative maximum response ∼30% of the haloperidol response[1]
Lowest tested clozapine concentration with significant surface D2R enhancement vs vehicle in the concentration–response datasettested significance threshold 3 μM (p < 0.01)[1]
Surface D2R after 10 μM clozapine for 24 h in the broader APD comparisoncomparison with vehicle Not significantly greater than vehicle[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration–response as plotted in Figure 2C; explicitly reported clozapine concentrations include 3, 10 and 30 μM. Multi-drug comparison: 10 μM clozapine.
Exposure duration
24 h
Method
Drug exposure followed by surface FLAG ELISA; vehicle and haloperidol/olanzapine comparators.
Reported limits
Vehicle composition is not specified in the selected procedures/caption. Individual lower concentrations are not transcribed from the curve.
Methods and source locations

Compound reported in the paper: Clozapine; Compound label in the paper: clozapine

Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.

Results: D2R surface expression after clozapine treatment; Figure 2C–F and caption; Experimental procedures: constructs, cell culture, FLAG ELISA and statistics; Discussion functional-assay limitation

Maximum clozapine-induced increase in cell-surface D2R relative to haloperidol response: Surface FLAG ELISA after 24 h; enhancement above vehicle normalized to response to 10 μM haloperidol; not percent total surface receptor. — Results paragraph for Figure 2C; Figure 2C caption

Lowest tested clozapine concentration with significant surface D2R enhancement vs vehicle in the concentration–response dataset: Dunnett multiple-comparison test; not an EC50. Figure 2C clozapine n = 50 at 10 μM, 12 at 3 and 30 μM, 6 at other concentrations; mean ± S.E. — Figure 2C caption

Surface D2R after 10 μM clozapine for 24 h in the broader APD comparison: Dunnett test; n = 32 for clozapine. Box plot uses median and full-range whiskers; separate dataset from Figure 2C. — Figure 2D caption

Partial inhibition of recombinant ErbB kinases

Biochemical assay · Commercial recombinant intracellular-domain ErbB1, ErbB2 and ErbB4 proteins; Tyr-Glu heteropolymer substrate [2]

Clozapine reduced phosphorylation of a synthetic substrate by truncated ErbB kinases under the authors’ non-reducing assay conditions. Inhibition remained partial over the tested range; a biochemical IC50 was not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lowest concentrations reported to significantly reduce recombinant kinase activitytested significance thresholds ErbB2: 3 μM; ErbB1 and ErbB4: 30 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0–100 μM
Exposure duration
30 min kinase reaction at 37 °C
Method
4 mM ATP; synthetic substrate phosphorylation enzyme immunoassay.
Vehicle
0.2% Triton X-100 in kinase reaction buffer; compounds dissolved in Triton X-100 for this assay.
Reported limits
Independent biological preparation count and a biochemical IC50 are not reported for Figure 5.
Methods and source locations

Compound reported in the paper: Clozapine; Compound label in the paper: CLZ

Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.

Materials and methods: Chemical compounds and In vitro kinase assay; Results: Direct inhibition of ErbB kinases; Figure 5 and caption

Lowest concentrations reported to significantly reduce recombinant kinase activity: Tyr-Glu substrate phosphorylation detected by phosphotyrosine enzyme immunoassay, 450 nm; one-way ANOVA/Tukey; n = 5 assay wells; mean ± SE. Thresholds are not IC50 values. — Results: Direct inhibition of ErbB kinases; Figure 5 and caption

Model-dependent inhibition of ligand-stimulated ErbB phosphorylation

Cell-based study · Human U87MG astroglioma cells (EGF/ErbB1); primary fetal rat cortical neurons (neuregulin-1/ErbB4); A431 cells as a limiting comparator [2]

Clozapine reduced ligand-induced ErbB phosphorylation in U87MG cells and cortical neurons. The reported cellular phosphorylation IC50 values differ between the two receptor/model combinations. EGF-stimulated A431 ErbB1 was less sensitive, limiting generalization across cell types.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EGF-induced Tyr1173 ErbB1 phosphorylation in U87MG cellscellular phosphorylation IC50 ~47 μM[2]
Neuregulin-1-induced Tyr1284 ErbB4 phosphorylation in cortical neuronscellular phosphorylation IC50 ~16 μM[2]
EGF-stimulated ErbB1 phosphorylation in A431 cells at 100 μM clozapine relative to EGF aloneresidual phosphorylation 66.2 ± 8.3%[2]

Literature-Reported Treatment Conditions

Treatment concentration
0–100 μM
Exposure duration
20–30 min antipsychotic pretreatment, followed by 5 min ligand stimulation in shared phosphorylation methods.
Method
Immunoblotting after EGF (U87MG/A431) or neuregulin-1 (neurons), 30 ng/mL ligand.
Vehicle
DMSO; vehicle control and unstimulated negative control.
Co-treatment
Ligand challenge, not a second therapeutic drug.
Reported limits
Dose-specific pretreatment time within the shared 20–30 min range is not assigned; cultures are sister cultures, not independent animals.
Methods and source locations

Compound reported in the paper: Clozapine; Compound label in the paper: CLZ

Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.

Materials and methods: Chemical compounds, Cell culture, Neuron culture and Immunoblotting; Results: Clozapine-dose-dependent inhibition; Figure 3; SI Figure S4 (PDF p. 6); Discussion: controversial actions

EGF-induced Tyr1173 ErbB1 phosphorylation in U87MG cells: Immunoblot phospho-ErbB1 normalized to total ErbB1; n = 3 sister cultures; mean ± SE. Author-reported approximate IC50; not enzyme potency. — Results: Clozapine-dose-dependent inhibition; Figure 3a

Neuregulin-1-induced Tyr1284 ErbB4 phosphorylation in cortical neurons: Immunoblot phospho-ErbB4 normalized to total ErbB4; n = 3 sister cultures; mean ± SE. Author-reported approximate IC50. — Results: Clozapine-dose-dependent inhibition; Figure 3b

EGF-stimulated ErbB1 phosphorylation in A431 cells at 100 μM clozapine relative to EGF alone: Exact number reported in Discussion; SI Figure S4 inspected; n = 3 cultures, mean ± SEM per caption. No exact number inferred from curve. — Discussion: controversial actions; SI Figure S4, PDF p. 6

Opposite response of basal ErbB1 phosphorylation in A431 cells

Cell-based study · Human A431 epidermoid carcinoma cells without EGF stimulation [2]

In the absence of EGF, 100 μM clozapine increased basal ErbB1 phosphorylation approximately twofold. This contrary response restricts the claim that clozapine inhibits cellular ErbB1 signaling to the tested model and stimulation conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal Tyr1173 ErbB1 phosphorylation in A431 cells at 100 μM clozapine relative to untreated baselinerelative basal phosphorylation twofold increase[2]

Literature-Reported Treatment Conditions

Treatment concentration
0–100 μM; opposite response described at 100 μM
Method
Clozapine alone, without EGF; normalized phosphorylation immunoblot.
Vehicle
DMSO in shared chemical methods; 0 μM clozapine baseline.
Reported limits
SI Figure S5 does not separately specify exposure duration; the ligand-stimulation sequence is not assigned to this ligand-free experiment.
Methods and source locations

Compound reported in the paper: Clozapine; Compound label in the paper: CLZ

Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.

SI Figure S5 and caption, PDF p. 7; Discussion: controversial actions; shared Chemical compounds, Cell culture and Immunoblotting methods

Basal Tyr1173 ErbB1 phosphorylation in A431 cells at 100 μM clozapine relative to untreated baseline: Immunoblot phospho-ErbB1/total ErbB1; mean ± SEM, n = 3 cultures; **P < 0.01, one-way ANOVA/Tukey in S5. Approximate fold description reported in Discussion, not a digitized decimal. — Discussion: controversial actions; SI Figure S5 and caption, PDF p. 7

Clozapine In Vivo Studies

In a within-subject control experiment in 13 male TH::Cre rats expressing VTA DIO-mCherry, clozapine (0.1 mg/kg, intraperitoneal; 30 min before testing) did not significantly change alcohol-cue port entries in a neutral context. This result is limited to the tested dose, model and behavioral endpoint. [3]

Low-dose clozapine control in alcohol-cue responding

Animal study · Male Long-Evans TH::Cre rats expressing control DIO-mCherry in the ventral tegmental area; n = 13, within-subject repeated measures [3]

In rats expressing the control construct rather than hM4Di, 0.1 mg/kg clozapine did not significantly affect conditioned-stimulus port entries relative to vehicle in the neutral-context test. The CNO comparison was a separate treatment in the same repeated-measures design, not combined with clozapine.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Interval × Treatment interaction for PreCS and CS port entries across vehicle, CNO and clozapine testsrepeated-measures ANOVA F(2, 24) = 0.431, p = 0.655, ηp² = 0.035[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once before the clozapine test
Treatment course
Test begins 30 min after dosing; one clozapine test per rat in a three-treatment within-subject design.
Vehicle
5% DMSO and 95% sterile 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Clozapine control
0.1 mg/kg
Vehicle; CNO 10 mg/kg assessed on a separate test, not in combination.No significant effect on CS port entries reported relative to vehicle; three-treatment Interval × Treatment interaction p = 0.655.[3]
Clozapine control
Model: Male Long-Evans TH::Cre rats expressing control DIO-mCherry in the ventral tegmental area; n = 13, within-subject repeated measures
Reported limits: Not designed as an equivalence study.
Methods and source locations

Compound reported in the paper: Clozapine; Compound label in the paper: clozapine

Compound-level research evidence; neither salt equivalence nor validation of the current Adooq product lot is established.

Results: control for potential off-target effects; Figure 2d and caption; Methods: Subjects, drugs/materials, Experiment 3 and Analyses and statistics

Interval × Treatment interaction for PreCS and CS port entries across vehicle, CNO and clozapine tests: n = 13 rats; aggregate three-treatment interaction, not a clozapine-only pairwise p value. All tests two-sided; mean ± s.e.m. with individual rats shown. — Figure 2d caption

Clozapine control · Figure 2d; Methods Experiment 3 and drugs/materials

Specifications

Manufacturer Adooq Bioscience
CAS Number 5786-21-0
Formula C18H19ClN4
Molecular Weight 326.8
Synonyms Clozaril; Fazaclo; HF 1854; Iprox; Klozapol; Leponex
SMILES
CN1CCN(CC1)C2=C3C=CC=CC3=NC4=C(N2)C=C(C=C4)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 59 mg/mL (180.52 mM)
Water Insoluble
Ethanol 29 mg/mL (88.73 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Clozapine Research References

  1. [1] Schrader JM, Irving CM, Octeau JC, et al. The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface The Journal of biological chemistry (2019). PMID: 30670597 DOI: 10.1074/jbc.ra118.004682 Source material
  2. [2] Kobayashi Y, Iwakura Y, Sotoyama H, et al. Clozapine-dependent inhibition of EGF/neuregulin receptor (ErbB) kinases Translational psychiatry (2019). PMID: 31371697 DOI: 10.1038/s41398-019-0519-1 Source material
  3. [3] Valyear MD, Glovaci I, Zaari A, et al. Dissociable mesolimbic dopamine circuits control responding triggered by alcohol-predictive discrete cues and contexts Nature communications (2020). PMID: 32724058 DOI: 10.1038/s41467-020-17543-4 Source material

Publications

6 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Madeleine S A Tan, .et al. , Mol Pharm, 2022, Sep 23 PMID: 36149013
  3. Madeleine S. A. Tan, .et al. , Gels, 2022, Jan; 8(1): 38 PMID: 35049572
  4. Milan D Valyear, .et al. , Nat Commun, 2020, Jul 28;11(1):3764 PMID: 32724058
  5. Yutaro Kobayashi, .et al. , Transl Psychiatry, 2019, 9:181 PMID: 31371697
  6. M.D. Valyear, .et al. , bioRxiv, 2018, 2018

Added to your cart

View Cart Checkout
Loading...